ABSTRACT

Provided is a configuration of a trispecific antigen-binding molecule. Further provided are a trispecific antigen-binding molecule that is constructed on the basis of the configuration and targets two tumor antigens, i.e. GPRC5D and BCMA, and T cell surface antigen CD3; a specific binding molecule or a fragment thereof that targets GPRC5D; a specific binding molecule or a fragment thereof that targets BCMA; a pharmaceutical composition containing the trispecific antigen-binding molecule or the specific binding molecule or the fragment thereof; and the relevant use thereof in the treatment of tumors.

No suitable figure